Kenya - English - Pharmacy and Poisons Board

f. hoffman-la roche ltd capitol hill towerscathedral road. p.o. box - rituximab - injection - rituximab 500mg - other antineoplastic agents: monoclonal antibodies

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - rituximab 10 mg/ml - concentrate for infusion - 10 mg/ml - active: rituximab 10 mg/ml excipient: citric acid monohydrate hydrochloric acid polysorbate 80 sodium chloride sodium hydroxide water for injection - latest regulatory activity

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - obinutuzumab, quantity: 1000 mg - injection, concentrated - excipient ingredients: poloxamer; histidine hydrochloride monohydrate; trehalose dihydrate; water for injections; histidine - chronic lymphocytic leukaemia,gazyva in combination with chlorambucil is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll).,follicular lymphoma,gazyva in combination with chemotherapy followed by gazyva maintenance is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.,gazyva in combination with bendamustine, followed by gazyva maintenance, is indicated for the treatment of patients with follicular lymphoma (fl) who did not respond to, or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.,pre-treatment to reduce the risk of cytokine release syndrome (crs) induced by glofitamab,gazyva is indicated as a pre-treatment to reduce the risk of cytokine release syndrome (crs) induced by glofitamab.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rituximab -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rituximab -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rituximab -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - rituximab -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - rituximab, quantity: 100 mg - injection, concentrated - excipient ingredients: sucrose; water for injections; histidine; polysorbate 80; histidine hydrochloride monohydrate; disodium edetate - non-hodgkin?s lymphoma,ruxience is indicated for treatment of patients with:,? cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma,,? cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma,,? cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia,ruxience is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis,ruxience in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy.,ruxience has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa),ruxience in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with ruxience have not been established.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - rituximab, quantity: 500 mg - injection, concentrated - excipient ingredients: histidine; water for injections; disodium edetate; polysorbate 80; histidine hydrochloride monohydrate; sucrose - non-hodgkin?s lymphoma,ruxience is indicated for treatment of patients with:,? cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin?s lymphoma,,? cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma,,? cd20 positive, diffuse large b-cell non-hodgkin?s lymphoma, in combination with chemotherapy.,chronic lymphocytic leukaemia,ruxience is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.,rheumatoid arthritis,ruxience in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy.,ruxience has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate.,granulomatosis with polyangiitis (wegener?s) (gpa) and microscopic polyangiitis (mpa),ruxience in combination with glucocorticoids is indicated for the induction of remission in patients with severely active granulomatosis with polyangiitis (gpa, also known as wegener?s granulomatosis) and microscopic polyangiitis (mpa). the efficacy and safety of retreatment with ruxience have not been established.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sandoz gmbh - rituximab - rituximab....100 mg / rituximab....500 mg